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Abstract
Background: Several hundred core outcome set (COS) projects have been systematically identified to date which,
if adopted, ensure that researchers measure and report those outcomes that are most likely to be relevant to users
of their research. The uptake of a COS by COS users will depend in part on the transparency and robustness of the
methods used in the COS development study, which would be increased by the use of a standardised protocol.
This article describes the development of the COS-STAP (Core Outcome Set-STAndardised Protocol Items)
Statement for the content of a COS development study protocol.
Methods: The COS-STAP Statement was developed following the Enhancing the Quality and Transparency Of
Health Research (EQUATOR) Network’s methodological framework for guideline development. This included
an initial item generation stage, a two-round Delphi survey involving more than 150 participants representing
three stakeholder groups (COS developers, journal editors and patient and public involvement researchers
interested in COS development), followed by a consensus meeting with eight voting participants.
Results: The COS-STAP Statement consists of a checklist of 13 items considered essential documentation in a
protocol, outlining the scope of the COS, stakeholder involvement, COS development plans and consensus processes.
Conclusions: Journal editors and peer reviewers can use the guidance to assess the completeness of a COS
development study protocol submitted for publication. By providing guidance for key content, the COS-STAP Statement
will enhance the drafting of high-quality protocols and determine how the COS development study will be carried out.
Keywords: Core outcome set, Guideline, Protocol
Introduction
Core outcome sets (COS), defined as an agreed standar-
dised set of outcomes that should be measured and
reported as a minimum [1], are being registered to sup-
port outcome choices in clinical trials, routine care [2]
and systematic reviews [3]. The number of COS studies
being published is increasing, but uptake of these cos in
research has been variable. However, the importance of
COS uptake has been acknowledged amongst key stake-
holders including trialists [4], trial funders [5], clinical
guideline developers [6], regulative authorities [7], payers
[8] and industry [9]. Development of the COS-STAR
(Core Outcome Set-STAndards for Reporting) guideline
aims to improve the quality of reporting COS develop-
ment studies [10].
The COS-STAD (Core Outcome Set-STAndards for
Development) minimum standard recommendations have
been previously identified as key considerations to im-
prove the methodological approach towards planning a
COS study [11]. Whilst making the protocol publicly
available for a COS development study was not agreed
upon as a COS-STAD minimum standard, it was sug-
gested that the availability of a protocol would ensure that
the methods are explicitly documented before the COS
development project starts, thus promoting research
integrity and transparency of the finalised COS. The avail-
ability of a protocol would also assist with the appraisal of
a COS against the COS-STAD minimum standards and
reduce arbitrary or informed decision-making during the
consensus process. Changes in any of the methods-based
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minimum standards during the consensus process may
lead to inappropriate decisions influencing the consensus
process, particularly if these changes are made with some
knowledge of the results. As an example, a change in the
consensus definition following the analysis of outcome
preference scores may lead to a different COS. This may
affect the credibility of the COS and may deter COS users
(e.g. trialists) from prioritising its adoption.
Few published COS listed in the COMET (Core
Outcome Measures in Effectiveness Trials, www.comet-ini
tiative.org) database have an associated publicly accessible
protocol. In an ongoing review, only two out of 42 cancer
COS studies identified in the COMET database published
between 1981 and 2016 had a protocol, although neither of
these protocols were published [12, 13]. However, a crude
search of PubMed has identified a stark increase in the
number of published COS protocols in more recent years,
with 31 identified in 2017. The rarity of COS protocols
may be due in part to the lack of knowledge about what to
include in a protocol, given there is no current guidance.
In response to this gap, we developed the COS-STAP
(Core Outcome Set-STAndardised Protocol Items) State-
ment as a framework for COS developers to document
their COS development plans. The checklist is relevant to
any consensus method chosen (e.g. Delphi survey, expert
panel meeting) or any combination of methods, but it con-
siders only the part of the process that determines ‘what’
outcomes should be measured within a particular research
or practice setting. Guidance about ‘how’ to select outcome
measurement instruments exists [14], although this guid-
ance does not include considerations for the protocol.
This paper summarises the development of the guideline,
presents the COS-STAP Statement and provides an
Explanation and Elaboration (E + E) supplement detailing
the rationale and supporting evidence of the importance of
each item, with examples from published COS protocols.
Development of the COS-STAP Statement
The COS-STAP Statement was developed in consultation
with three key stakeholder groups with complementary
roles: COS developers, journal editors and those with
interest in patient and public involvement (PPI) and
participation in COS research (i.e. a separate subgroup of
COS developers). As detailed in subsequent sections, the
Statement was developed by generating an initial list of
protocol items, undertaking a two-round Delphi survey
and holding a consensus meeting—an approach that fol-
lows the Enhancing the Quality and Transparency Of
Health Research (EQUATOR) Network’s methodological
framework for guideline development [15].
Development of the preliminary list of protocol items
The process began with a preliminary checklist of 35
items derived from the personal experiences of COS
development amongst the project management group
(listed study authors). The COS-STAR reporting guide-
line [10] was also consulted when developing the initial
list, because many protocol items would mirror applic-
able items at the reporting stage. The list of items was
grouped into domains and subdomains to reflect the
stages of planning a COS study (Additional file 1).
Delphi survey
This preliminary list of items was included in an inter-
national two-round Delphi survey in order to ascertain
their importance. The survey participants included the
three key stakeholder groups, chosen to encompass
those who have experience in COS development or pro-
cessing the publication of COS manuscripts. Persona-
lised invitations by email were sent to (1) 288 lead
investigators of a published COS or those involved with
an ongoing COS study in the COMET database, with a
request to forward the invitation to any methodologists
involved; (2) editors-in-chief of 162 journals where COS
studies have been published; and (3) ten PPI researchers
involved with COS. The aim was to recruit as many in-
dividuals from each stakeholder group as possible for
the Delphi exercise.
Delphi participants rated the importance of each item
on a scale from 1 (not important) to 9 (critically import-
ant). In round 1 of the Delphi study, participants could
suggest new items to be included in the second round,
as well as make suggestions to improve the clarity of the
wording of existing items (Additional file 1). In round 2,
each participant who participated in round 1 was shown
the number of respondents and distribution of scores for
each item, for all stakeholder groups separately, together
with their own score from round 1. An additional 65
items were suggested in round 1, ten of which were
scored in round 2 following the removal of duplicate
suggestions and review by the project management
group (Additional file 2).
The consensus criteria were consistent with our other
related guidance work [10, 11] and were defined a priori
in the research plan submitted to the Ethics Committee.
Consensus was achieved if at least 70% of the voting par-
ticipants from each stakeholder group scored between 7
and 9. COS developers (n = 133), journal editors (n = 15)
and COS PPI researchers (n = 10) participated in both
rounds (Additional file 3); 121 were from Europe, 27
from the USA/Canada, six Oceania and four Asia. The
variable number of respondents per stakeholder group
did not affect the results since feedback in round 2 was
presented by group. The Delphi process was conducted
and managed using DelphiManager software developed
by the COMET Initiative [16].
The consensus meeting was a half-day event held in
London, UK, in July 2018 with eight international voting
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participants, including COS developers (n = 4), journal
editors (n = 2) and COS PPI researchers (n = 2). Individ-
uals were broadly selected based on completion of both
rounds of the Delphi survey, COS development experi-
ence (completed versus ongoing developers) and, in the
case of journal editors, those who regularly publish COS
protocols. If an individual could not attend, he/she was
replaced by someone else from the same stakeholder
group wherever possible. Three UK participants attended
the consensus meeting in person whilst the others (2 UK,
1 European and 2 USA participants) joined the meeting
via Adobe Connect web conferencing software [17]. Two
additional participants (one facilitator who chaired the
meeting and one note taker) attended the meeting but did
not participate in the discussion or voting.
The Delphi results for all 45 items were presented to
the consensus meeting participants prior to the meeting
(Additional file 3). At the start of the meeting, it was
agreed by the participants that 13 items should be auto-
matically included in the final COS-STAP checklist
because each of these items reached consensus amongst
all stakeholder groups in the Delphi survey, and all
were included in the COS-STAR reporting guideline
(Additional file 4). Seven items were excluded with lim-
ited discussion because less than 50% of participants
from each stakeholder group thought the item was crit-
ical for inclusion, and none of these were included in
the COS-STAR reporting guideline (Additional file 4).
The Delphi survey results from the remaining 25 items
were then presented to the consensus meeting partici-
pants; each item was discussed and then voted on, and
retained if more than 70% of the voting participants (i.e.
at least 6 of the 8 voting participants) scored between 7
and 9. Voting was undertaken using Poll Everywhere
[18], which allowed remote voting via a weblink. Results
from the voting and key discussion points are presented
in Additional file 4.
After all items were discussed, the meeting facilitator
introduced one additional item (item 46) relating to how
COS developers planned to disseminate results to study
participants and COS users. This item was suggested by
a number of participants in the first round of the Delphi
survey, but due to an oversight it was not included in
round 2. The consensus panel agreed to discuss and vote
on this item, and consensus was achieved that it should
be included in the Statement (Additional file 4).
During the consensus meeting, participants discussed
the importance of distinguishing between items to be in-
cluded in a published protocol, for which this guideline
has been developed, and the additional items that are
not pertinent for inclusion in the Statement but may still
need to be considered in relation to the COS develop-
ment process itself. Examples of the latter are described
in the points below. The need to merge some items and
create subitems was noted, together with suggestions for
the explanatory document to enhance the usefulness of
the final Statement. Specifically, the following amend-
ments were discussed and agreed by the consensus
meeting panel during the meeting:
1. Stakeholders. There were eight items under this topic,
and whilst it was agreed that all could provide useful
information, some were considered too specific to be
included and four were voted out (item numbers 14,
16, 18, 20, Additional file 4). Of the four remaining
items (item numbers 13, 15, 17, 19, Additional file 4),
one item covering which stakeholder groups are to be
involved in the COS development process (including
rationale), and a description of how individuals
from within each stakeholder group will be
identified should be included. The E + E
document will discuss the number of planned
participants within each stakeholder group and
any roles, inclusive of consensus participation or
study design roles.
2. Outcome scoring/feedback summary. To include a
summary of how participants would receive any
feedback during the consensus process as part of
how the consensus results.
3. Missing data. To include one item reflecting
missing data in the Statement, with specific sources
of missing data (attrition and partial responses)
highlighted in the E + E document.
4. Ethics and informed consent. To combine aspects
of research ethics committee (REC)/institutional
review board (IRB) approvals and informed consent
as a single item.
Following the meeting, a draft of the Statement was cir-
culated to the project management group (study authors)
and the remainder of the COS-STAP Group who partici-
pated in the consensus meeting. All comments and
revisions were taken into consideration and the checklist
revised accordingly. The process of obtaining feedback
and refining the checklist was repeated until no further
changes were needed.
The COS-STAP Statement
The 13-item COS-STAP Statement presented in Table 1
applies to COS development studies where the aim of the
study is to decide what outcomes should be included in
the COS; it does not extend to cover plans on how those
outcomes should be defined or measured. The items are
categorised into six main sections: Title/Abstract, Intro-
duction, Methods, Analysis, Ethics and Dissemination,
Administrative Information.
The COS-STAP development process ensured that the
items complement the COS-STAR reporting guideline
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whenever possible, facilitating the transition of a COS
protocol to the COS final report. The COS-STAP State-
ment covers the minimum protocol items needed to be
included in a published protocol and is designed to be
applicable regardless of the planned consensus method-
ology (inclusive of mixed methods). The included items
should capture all sources of potential deviations that
may lead to inappropriate decisions influencing the
consensus process. In certain circumstances, and at the
discretion of the COS developers, additional details may
be warranted for inclusion in the protocol in order to
carry out the study as planned.
In the accompanying E + E document (Additional file 5),
explanations are provided for the meaning and rationale
for each protocol item, with examples provided from pub-
lished COS protocols.
Discussion
Despite the fact that a study protocol did not reach con-
sensus as part of the COS-STAD minimum standards for
COS development, it is still considered good research
practice in general to develop a protocol before the start
of a study and make it publicly available on a suitable plat-
form. The COS-STAP Statement provides international
consensus-based guidance on what information should be
included in a published protocol for COS development
studies. The checklist comprises 13 minimum items to be
included in COS protocols to promote transparency. We
also prepared the COS-STAP E + E document to provide
an explanation of each of the COS-STAP Statement items
and to provide good examples of how these items have
been previously addressed in published COS protocols.
We strongly recommend that COS developers consult the
E + E guidance when developing their COS protocol using
COS-STAP to optimise the study design.
During the development of the COS-STAP Statement,
we ensured that there was adequate harmonization be-
tween key methodological items that were included in
the COS-STAR reporting guideline. This ensures a
smooth transition from a COS protocol into the final re-
port of a COS study. Eleven of the 13 COS-STAP items
have a corresponding COS-STAR item. Where it was felt
that the wording, context or understanding of items
could be improved from the COS-STAR Statement, we
modified the text; e.g. the setting (a term used in
COS-STAR) in which the COS is to be applied was com-
monly misunderstood by the consensus meeting panel,
and it was felt that ‘context of use’ would be more ap-
propriate. We also extended item 8 to include ‘how par-
ticipants will receive feedback during the consensus
process’. Whilst this may not be important for final COS
reporting, it has been previously shown that different
feedback approaches may influence the final core set
[19], and therefore the planned feedback approach to be
Table 1 Core Outcome Set-STAndardised Protocol Items: the
COS-STAP Statement
TITLE/ABSTRACT
Title 1a Identify in the title that the paper describes the
protocol for the planned development of a COS
Abstract 1b Provide a structured abstract
INTRODUCTION
Background
and objectives
2a Describe the background and explain the
rationale for developing the COS, and identify the
reasons why a COS is needed and the potential
barriers to its implementation
2b Describe the specific objectives with reference to
developing a COS
Scope 3a Describe the health condition(s) and
population(s) that will be covered by the COS
3b Describe the intervention(s) that will be covered
by the COS
3c Describe the context of use for which the COS is
to be applied
METHODS
Stakeholders 4 Describe the stakeholder groups to be involved
in the COS development process, the nature of
and rationale for their involvement and also how
the individuals will be identified; this should cover
involvement both as members of the research team
and as participants in the study
Information
sources
5a Describe the information sources that will be used
to identify the list of outcomes. Outline the
methods or reference other protocols/papers
5b Describe how outcomes may be dropped/
combined, with reasons
Consensus
process
6 Describe the plans for how the consensus process
will be undertaken
Consensus
definition
7a Describe the consensus definition
7b Describe the procedure for determining how
outcomes will be added/combined/dropped from
consideration during the consensus process
ANALYSIS
Outcome
scoring/
feedback
8 Describe how outcomes will be scored and
summarised, describe how participants will receive
feedback during the consensus process
Missing data 9 Describe how missing data will be handled during
the consensus process
ETHICS and DISSEMINATION
Ethics
approval/
informed
consent
10 Describe any plans for obtaining research ethics
committee/institutional review board approval in
relation to the consensus process and describe
how informed consent will be obtained (if relevant)
Dissemination 11 Describe any plans to communicate the results to
study participants and COS users, inclusive of
methods and timing of dissemination
ADMINISTRATIVE INFORMATION
Funders 12 Describe sources of funding, role of funders
Conflicts of
interest
13 Describe any potential conflicts of interest within
the study team and how they will be managed
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taken should be described in the COS protocol. More
information on different methods of providing feedback
and on COS development consensus methodology in
general can be found in the COMET Handbook [20].
We added two new items to the COS-STAP Statement
that were not included in COS-STAR. Item 9 related to
how missing data would be handled during the consen-
sus process. Similarly to the point made about item 8,
missing data may lead to bias (and the final COS) if
missing data is informed by the results, for example, if a
participant decided not to respond in a round of Delphi
because their opinions differed from their peers. De-
scribing approaches for dealing with missing data (e.g.
how to deal with views from participants who have not
scored all outcomes) at the protocol stage will help avoid
any arbitrary decisions that developers might be forced
to make during the consensus process. Item 11 related
to dissemination strategies for the study results, and it
was introduced at the consensus meeting stage. The
item was supported by the majority of consensus meet-
ing participants and was a mandatory section for BMJ
Open [21], a journal which publishes a large number of
COS protocols.
COS-STAP focusses on the main methodological plans
for developing a COS. However, during the discussion of
dissemination plans, the importance of COS implementa-
tion was raised as being relevant to the development
process, which might include both the intended audience
and users of COS (e.g. trialists) as stakeholders, and to the
pathways to reach these stakeholders. The consensus
meeting group decided that developing an implementa-
tion plan was a separate issue, but at the COS develop-
ment stage, COS developers should consider how the
development might underpin the subsequent implementa-
tion of the COS. For this reason it was agreed that any
potential barriers to COS implementation should be
discussed (item 2a). For example, the location of many
participants involved in COS development has primarily
been in North America and Europe [22], and this may
affect the perceived relevance of the COS in groups who
are underrepresented, such as those from Latin America,
Asia Pacific, Africa and low- and middle-income coun-
tries, and therefore potentially subsequent uptake.
The study had two limitations. The participation rate in
the international Delphi survey appeared to be low, par-
ticularly for journal editors, although retention in round 2
was above 85% overall, with no evidence of attrition bias.
Due to logistical constraints in arranging a consensus
meeting, only a small group of eight participants voted on
the items. To address this limitation, we structured the
meeting such that items that reached the ‘consensus in’
criteria for the larger group of Delphi participants for all
stakeholder groups were dealt with collectively, and it was
decided that all of these should be included in the final
COS-STAP Statement. Those unable to attend the meet-
ing also had the opportunity to comment on the final
items and processes of the meeting.
The success of the COS-STAP Statement requires the
support of COS developers utilising the guideline. COS
developers who register their study on the COMET data-
base will be alerted to the existence of the COS-STAP
Statement. We anticipate that widespread adoption of the
COS-STAP Statement will facilitate improvement in the
content of COS development studies and provide editorial
support for assessing the completeness of submitted COS
protocols for publication. Readers are invited to submit
comments, criticisms, experiences and recommendations
via the COMET website (http://www.comet-initiative.org/
contactus), which will be considered for future refinement
of the COS-STAP Statement.
Additional files
Additional file 1: Preliminary checklist of 35 items derived from the
personal experiences of COS development by the project management
group. (DOCX 34 kb)
Additional file 2: Additional items suggested by Delphi participants in
round 1. (DOCX 31 kb)
Additional file 3: Consensus matrix for round 1 and round 2 of the
COS-STAP Delphi survey. (DOCX 59 kb)
Additional file 4: COS-STAP consensus meeting results/discussion.
(DOCX 42 kb)
Additional file 5: Explanation and Elaboration document for COS-STAP.
(DOCX 253 kb)
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